{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:40Z","timestamp":1787009440957,"version":"build-2736575974"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Merck & Co., Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adult vaccination programs are suboptimal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pneumococcal vaccination history, and healthcare contact were assessed in patients with invasive pneumococcal disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 229 cases, 14% were vaccinated. Observed mortality was 20.1%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Numerous missed vaccination opportunities were identified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofac075","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T11:30:48Z","timestamp":1647430248000},"source":"Crossref","is-referenced-by-count":5,"title":["Missed Pneumococcal Vaccination Opportunities in Adults With Invasive Pneumococcal Disease in a Community Health System"],"prefix":"10.1093","volume":"9","author":[{"given":"Paul S","family":"Schulz","sequence":"first","affiliation":[{"name":"Norton Healthcare, Louisville, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-2735","authenticated-orcid":false,"given":"Sarah E","family":"Moore","sequence":"additional","affiliation":[{"name":"Norton Healthcare, Louisville, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Smith","sequence":"additional","affiliation":[{"name":"Norton Healthcare, Louisville, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Javed","sequence":"additional","affiliation":[{"name":"Norton Healthcare, Louisville, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8459-0025","authenticated-orcid":false,"given":"Ashley M","family":"Wilde","sequence":"additional","affiliation":[{"name":"Norton Healthcare, Louisville, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"2022031615304097900_CIT0001","first-page":"11.1","article-title":"Pneumococcal","volume-title":"VPD Surveillance Manual","author":"Gierke","year":"2017"},{"key":"2022031615304097900_CIT0002","first-page":"255","article-title":"Pneumococcal disease","volume-title":"Epidemiology and Prevention of Vaccine Preventable Diseases","author":"Hamborsky","year":"2015","edition":"13"},{"key":"2022031615304097900_CIT0003","author":"Nationally Notifiable Infectious Diseases and Conditions, United States.","year":"2018"},{"key":"2022031615304097900_CIT0004","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031615304097900_CIT0005","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.vaccine.2017.01.032","article-title":"Exploratory efficacy endpoints in the community-acquired pneumonia immunization trial in adults (CAPiTA).","volume":"35","author":"Webber","year":"2017","journal-title":"Vaccine"},{"key":"2022031615304097900_CIT0006","first-page":"e00309","article-title":"Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States.","volume":"2","author":"Simonson","year":"2011","journal-title":"MBio"},{"key":"2022031615304097900_CIT0007","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14760584.2018.1413354","article-title":"Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution.","volume":"17","author":"Izurieta","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"2022031615304097900_CIT0008","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1016\/j.vaccine.2019.04.017","article-title":"Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: a case-control study.","volume":"37","author":"Kim","year":"2019","journal-title":"Vaccine"},{"key":"2022031615304097900_CIT0009","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S2213-2600(16)00052-7","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study.","volume":"4","author":"Moore","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2022031615304097900_CIT0010","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.vaccine.2017.04.032","article-title":"Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: a systematic review of literature.","volume":"35","author":"Tsaban","year":"2017","journal-title":"Vaccine"},{"key":"2022031615304097900_CIT0011","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1401914","article-title":"Effects of vaccination on invasive pneumococcal disease in South Africa.","volume":"371","author":"Von Gottberg","year":"2014","journal-title":"N Engl J Med"},{"key":"2022031615304097900_CIT0012","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.diagmicrobio.2013.12.016","article-title":"Serotype distribution and antibiotic resistance of Streptococcus pneumoniae isolated from invasive infections after optional use of the 7-valent conjugate vaccine in Korea, 2006-2010.","volume":"78","author":"Cho","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2022031615304097900_CIT0013"},{"key":"2022031615304097900_CIT0014","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine among adults aged \u226565: updated recommendations of the advisory committee on immunization practices.","volume":"68","author":"Matanock","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022031615304097900_CIT0015","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/thoraxjnl-2015-206780","article-title":"Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking. diabetes, and\/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease.","volume":"70","author":"Torres","year":"2015","journal-title":"Thorax"},{"key":"2022031615304097900_CIT0016","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.vaccine.2017.02.026","article-title":"Risk stacking of pneumococcal vaccination indications increases mortality in unvaccinated adults with Streptococcus pneumoniae infections.","volume":"35","author":"Morton","year":"2017","journal-title":"Vaccine"},{"key":"2022031615304097900_CIT0017","doi-asserted-by":"crossref","first-page":"ofv020","DOI":"10.1093\/ofid\/ofv020","article-title":"Rethinking risk for pneumococcal disease in adults: the role of risk stacking.","volume":"2","author":"Pelton","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2022031615304097900_CIT0018","doi-asserted-by":"crossref","first-page":"e0220951","DOI":"10.1371\/journal.pone.0220951","article-title":"Risk factor profiles and clinical outcomes for children and adults with pneumococcal infections in Singapore: a need to expand vaccination policy?","volume":"14","author":"Martinez-Vega","year":"2019","journal-title":"PLoS One"},{"key":"2022031615304097900_CIT0019","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1016\/j.vaccine.2016.07.003","article-title":"Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults.","volume":"34","author":"Baxter","year":"2016","journal-title":"Vaccine"},{"key":"2022031615304097900_CIT0020","author":"Immunization Registry (KYIR)."},{"key":"2022031615304097900_CIT0021","first-page":"51208","article-title":"Capsular serotyping of Streptococcus pneumoniae using the Quellung reaction.","volume":"84","author":"Habib","year":"2014","journal-title":"J Vis Exp"},{"key":"2022031615304097900_CIT0022","doi-asserted-by":"crossref","first-page":"6772","DOI":"10.1016\/j.vaccine.2018.09.024","article-title":"U.S. clinicians\u2019 and pharmacists\u2019 reported barriers to implementation of the Standards for Adult Immunization Practice.","volume":"36","author":"Srivastav","year":"2018","journal-title":"Vaccine"},{"key":"2022031615304097900_CIT0023","author":"Merck & Co."},{"key":"2022031615304097900_CIT0024","first-page":"253","article-title":"Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.","volume":"59","author":"Centers for Disease Control and Prevention (CDC).","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022031615304097900_CIT0025","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","article-title":"Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study.","volume":"14","author":"Andrews","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2022031615304097900_CIT0026","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/pathogens9050396","article-title":"Characteristics of serotype 3 invasive pneumococcal disease before and after universal childhood immunization with PCV13 in Massachusetts.","volume":"9","author":"Lapidot","year":"2020","journal-title":"Pathogens"},{"key":"2022031615304097900_CIT0027","first-page":"6","article-title":"Develop a pneumococcal vaccination program.","volume":"15","author":"Gill","year":"2019","journal-title":"Pharmacy Purchasing and Products"},{"key":"2022031615304097900_CIT0028","author":"Centers for Disease Control and Prevention."},{"key":"2022031615304097900_CIT0029","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.15585\/mmwr.mm6845a2","article-title":"Tobacco product use and cessation indicators among adults \u2013 United States, 2018.","volume":"68","author":"Creamer","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022031615304097900_CIT0030","volume-title":"Report of the SAGE Working Group on Vaccine Hesitancy","author":"Strategic Advisory Group of Experts on Immunization.","year":"2014"},{"key":"2022031615304097900_CIT0031","first-page":"175","article-title":"Addressing vaccine hesitancy: clinical guidance for primary care physicians working with parents.","volume":"65","author":"Shen","year":"2019","journal-title":"Can Fam Physician"},{"key":"2022031615304097900_CIT0032","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1370\/afm.1405","article-title":"Interventions to improve influenza and pneumococcal vaccination rates among community-dwelling adults: a systematic review and meta-analysis.","volume":"10","author":"Lau","year":"2012","journal-title":"Ann Fam Med"},{"key":"2022031615304097900_CIT0033","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/14760584.2017.1242419","article-title":"Evaluating the costs and benefits of pneumococcal vaccination in adults.","volume":"16","author":"Porchia","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"2022031615304097900_CIT0034","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1016\/j.vaccine.2013.10.024","article-title":"Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.","volume":"31","author":"Cho","year":"2013","journal-title":"Vaccine"},{"key":"2022031615304097900_CIT0035","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3810\/pgm.2012.05.2550","article-title":"Identifying barriers to adult pneumococcal vaccination: an NFID task force meeting.","volume":"124","author":"Rehm","year":"2012","journal-title":"Postgrad Med"},{"key":"2022031615304097900_CIT0036","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3122\/jabfm.2018.01.170216","article-title":"Primary care physicians\u2019 struggle with current adult pneumococcal vaccine recommendations.","volume":"31","author":"Hurley","year":"2018","journal-title":"J Am Board Fam Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/4\/ofac075\/42924584\/ofac075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/4\/ofac075\/42924584\/ofac075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T11:31:15Z","timestamp":1647430275000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac075\/6549658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac075","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2022,3,16]]},"article-number":"ofac075"}}